Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report
Susan L Cohn, Andrew D J Pearson, Wendy B London, et al.
Cancers
|
November 13, 2021
Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care
Pablo Gargallo, Silvestre Oltra, Yania Yáñez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2009
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification
Bruno De Bernardi, Mary Gerrard, Luca Boni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2010
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study
Ruth Ladenstein, Dominique Valteau-Couanet, Penelope Brock, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 20, 2020
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
Loredana Amoroso, Victoria Castel, Gianni Bisogno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1
Hervé Rubie, Bruno De Bernardi, Mary Gerrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 21, 2021
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, et al.
British Journal of Cancer
|
May 15, 2018
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
Ana P Berbegall, Dominik Bogen, Ulrike Pötschger, et al.
The Lancet. Oncology
|
November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
Cancers
|
February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report
Susan L Cohn, Andrew D J Pearson, Wendy B London, et al.
Cancers
|
November 13, 2021
Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care
Pablo Gargallo, Silvestre Oltra, Yania Yáñez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2009
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification
Bruno De Bernardi, Mary Gerrard, Luca Boni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2010
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study
Ruth Ladenstein, Dominique Valteau-Couanet, Penelope Brock, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 20, 2020
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
Loredana Amoroso, Victoria Castel, Gianni Bisogno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1
Hervé Rubie, Bruno De Bernardi, Mary Gerrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 21, 2021
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, et al.
British Journal of Cancer
|
May 15, 2018
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
Ana P Berbegall, Dominik Bogen, Ulrike Pötschger, et al.
The Lancet. Oncology
|
November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
Cancers
|
February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
Page
of 8